Clinical trial

Drug Elution Profile and Minimum Inhibitory Concentration of Antibiotic-loaded Cement After Primary Total Knee Arthroplasty

Name
MAUS21D.1213
Description
This study will provide us with clear information about the postoperative concentration of antibiotic reached in synovial fluid, thereby helping surgeons to determine if concentration could potentially prevent the growth and regrowth of common infecting microorganisms (based on their MIC and MBEC). There is a need to define the actual benefit of antibiotic-loaded bone cement, because the addition of antibiotic can reduce its mechanical strength. Moreover, if sub-therapeutic antibiotic levels are achieved, this could facilitate the emergence of resistant bacterial strains. Amidst the transition towards value-based care, our research will enable surgeons to decide whether antibiotic-loaded cement is truly cost-effective in the prevention of PJI.
Trial arms
Trial start
2022-06-20
Estimated PCD
2023-11-30
Trial end
2023-11-30
Status
Completed
Phase
Early phase I
Treatment
total knee arthroplasty
Participants will have total knee arthroplasty
Arms:
Group A (Control-negative group), Group B (tobramycin group), Group C (gentamicin group), Group D (Control-positive group)
Tobramycin
Total knee arthroplasty using Stryker Surgical Simplex P with tobramycin
Arms:
Group B (tobramycin group)
Gentamicin
Total knee arthroplasty using Huraeus Palacos R+G cement containing gentamicin
Arms:
Group C (gentamicin group)
Antibiotic cement spacer
participants getting an antibiotic-loaded cement spacer during surgery comprised of vancomycin and tobramycin.
Arms:
Group D (Control-positive group)
Size
50
Primary endpoint
Antibiotic concentration
24 hours
Eligibility criteria
Inclusion Criteria: * All participants undergoing cemented primary total knee arthroplasty (TKA) who are 18 years or older. Exclusion Criteria: * Withdrawal of informed consent, * allergy to any of the study medications or to bone cement, * use of antibiotics within 4 weeks before collecting the samples (not including perioperative antimicrobial prophylaxis), * high risk of infection, * history of peri-articular injections for multimodal pain management.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 50, 'type': 'ACTUAL'}}
Updated at
2024-04-30

1 organization

2 products

1 indication

Product
Tobramycin
Product
Gentamicin